Bullous Pemphigoid
Conditions
Brief summary
Clinical observation frequently shows a paradoxical effect of topical corticosteroids in charge of a sudden melting of edema in the first days of treatment, which could be due to mobilization of extracellular. No study has shown the value of this measure in patients treated with topical steroids. This uncertainty, coupled with the observation of the paradoxical effects of topical steroids on edema are some patients that despite the systemic absorption of clobetasol propionate, a salt-free diet is not currently recommended practice.
Detailed description
The main objective of the study is to evaluate whether there is fluid retention after introduction of clobetasol propionate treatment from 10 g/day dosage to 40 g / day in patients with bullous pemphigoid. Bio-impedance is a noninvasive device for measuring with an electric current of low intensity the different volumes of the human body. A preliminary experiment of impedance measurements in some patients with bullous pemphigoid (examination requested as part of a nutritional assessment) showed that these patients had mostly a total water loss without dehydration, corresponding to a significant undernutrition during 1 month of treatment, possibly related to muscle wasting and protein loss by skin erosions without obvious argument for fluid retention, justifying reproduce these measures on a larger number of patients and the other to accurately assess the evolution of nutritional parameters during the first month of treatment.
Interventions
PROCEDUREImpedance analysis
Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate. impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle
DRUGClobetasol Propionate cream treatment
clobetasol propionate treatment initiated following French recommendations
Sponsors
University Hospital, Rouen
Société de Dermatologie Française
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with age higher than 18 * Patient with bullous pemphigoid, * Patient treated by local corticosteroid therapy (clobetasol propionate cream) but not yet processed or for less than 48 hours, * Signed informed consent. * Patient affiliated to Social Security Regimen * Effective contraception in women of childbearing age (for postmenopausal women, confirmatory diagnosis of menopause will be collected)
Exclusion criteria
* Concomitant treatment with corticosteroids * Recent introduction or recent (\<6 weeks) treatment with diuretics, angiotensin-converting enzyme, receptor antagonist or anti-angiotensin renin (aliskiren) * contraindication to the use of Clobetasol propionate (DERMOVAL and CLARELUX) * Patient on salt diet (\<or = to 5 g / d) * Patients carry a defibrillator or a pace maker * Amputated Patient * Pregnant and lactating * Patient with Urinary Incontinency * Recent heart decompensation in the last 6 weeks * known Nephrotic Syndrome * known or Severe hepatic impairment * Hypoalbuminaemia less than 20 g / l
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in fluid retention at day 30 | Day 30 | Change from Baseline in extra-cellular water volume at day 30 measured by bioimpedance analysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in fluid retention at day 7 | Day 7 | Change from Baseline in extra-cellular water volume at day 7 measured by bioimpedance analysis |
| Weight variation between day 1 and day 30 | Day 30 | — |
| Urinary Sodium level variation between day 1 and day 30 | Day 30 | — |
| Urinary creatinin level variation between day 1 and day 30 | Day 30 | — |
| Brain Natriuretic Peptide level variation between day 1 and day 30 | Day 30 | — |
| Change from Baseline in nutritional parameters at day 30 | Day 30 | bioimpedance analysis, C Reactive Protein level, albumin level, daily diet diary, Buzby index |
| Change from Baseline in bullous pemphigoid disease severity index at day 30 | Day 30 | BPDAI questionary assessment |
| Change from Baseline in bullous pemphigoid disease severity index at day 7 | Day 7 | BPDAI questionary assessment |
| Change from Baseline in corticoid administration dosage at days 30 | Day 30 | Evaluation of corticoid dosage between day 1 and day 30 |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORSophie Duvert Lehembre, Doctor
clinique dermatologique du chu de Rouen
Outcome results
None listed